Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.

Raghunathan, Suchi; Goyal, Ramesh K; Patel, Bhoomika M

Raghunathan, Suchi; Goyal, Ramesh K; Patel, Bhoomika M.

Affiliation

Raghunathan S; a Institute of Pharmacy, Nirma University, Ahmedabad 382 481, India.
Goyal RK; b Delhi Pharmaceutical Sciences Research University, Delhi, India.
Patel BM; a Institute of Pharmacy, Nirma University, Ahmedabad 382 481, India.

Can J Physiol Pharmacol ; 95(3): 260-267, 2017 Mar.

Article in En | MEDLINE | ID: mdl-28177689

Subject(s)

Cardiomegaly/prevention & control; Histone Deacetylase 2/antagonists & inhibitors; Histone Deacetylase Inhibitors/pharmacology; Myocardium/enzymology; Valproic Acid/pharmacology; Ventricular Remodeling/drug effects; Animals; Biomarkers/blood; Cardiomegaly/enzymology; Cardiomegaly/pathology; Cardiomegaly/physiopathology; DNA, Mitochondrial/genetics; DNA, Mitochondrial/metabolism; Disease Models, Animal; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Hemodynamics/drug effects; Histone Deacetylase 2/genetics; Histone Deacetylase 2/metabolism; Histone Deacetylases/genetics; Histone Deacetylases/metabolism; Lipids/blood; Male; Myocardium/pathology; Oxidative Stress/drug effects; Rats, Wistar; Time Factors

Key words

HDAC de classe I; HDAC de classe II; class I HDAC; class II HDAC; constriction partielle de l'aorte abdominale; magnesium valproate; partial abdominal aortic constriction (PAAC); valproate de magnésium

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Valproic Acid / Cardiomegaly / Ventricular Remodeling / Histone Deacetylase 2 / Histone Deacetylase Inhibitors / Myocardium Type of study: Prognostic_studies Limits: Animals Language: En Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google